Navigation Links
Peptimmune Announces First Close of Series D Private Financing
Date:1/17/2008

CAMBRIDGE, Mass., Jan. 17 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced that it has completed a first close of $8.2 million of a Series D preferred stock offering with its investor syndicate led by New Enterprise Associates, MPM Capital, Hunt Ventures L.P., Boston Medical Investors and Silicon Valley Bank Capital, as well as certain other investors, including its Chairman of the Board. The Company expects a second close in Q2/2008, which may involve an additional new investor. The proceeds of the financing are primarily being used to advance clinical development of Peptimmune's PI-2301 for the treatment of multiple sclerosis.

"We are pleased with the level of continuing support from our existing investors and the opportunity to expand our syndicate," stated Thomas P. Mathers, President and CEO. "The Series D investment will provide the necessary capital to complete two clinical trials by the end of 2008: the current single ascending dose in healthy volunteers and a multiple ascending dose in multiple sclerosis patients, expected to start in Q2/08. The completion of these two studies will offer proof of principal for PI-2301, which is a second generation copolymer targeted at treating patients with relapsing and remitting multiple sclerosis."

Financing Two Clinical Trials in Multiple Sclerosis

Peptimmune is currently completing its Phase I single ascending dose study for PI-2301, a double blind placebo controlled randomized study that involves 56 healthy male volunteers who will receive the drug in eight escalating dose cohorts. Following establishment of safety at potentially therapeutic doses, the Company will initiate its first repeat dose study in multiple sclerosis patients in Q2/2008, where it will explore safety, pharmacokinetics and pharmacodynamics over eight to twelve weeks of dosing.

About PI-2301

PI-2301 is a second generation peptide copolymer from a similar compound class as
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Vasogen Announces 2007 Year-End Results
4. RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
5. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
6. Healthcare Technologies Ltd. (NASDAQ: HCTL) Announces Extension of Letters of Intent to Acquire Majority Interest in Two Ethanol Plants
7. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
8. Hagens Berman Sobol Shapiro Announces Proposed Class-Action Lawsuit Against CellCyte
9. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
10. Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend
11. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... (PRWEB) May 20, 2013 Kitware, a ... visualization tool that enables the exploration of hospital ... created in response to the recent release of “Medicare ... the top 100 most-billed procedures from the Centers for ... costs for similar procedures at hospitals across the country ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Topricin ... BioMedics, Inc., has been listed among nationally recommended ... an initiative conducted by "U.S. News" Health in ... earned the “No. 1 Pharmacists Recommended designation” ... other national OTC brands, and is the only ...
(Date:5/17/2013)... a world-leading provider of scientific, technical and medical information ... recent study in Reproductive BioMedicine Online ... with an abnormal chromosomal composition can be identified by ... thereby classifying the risk of genetic abnormality without a ... undertaken a retrospective study, using their predictive model to ...
(Date:5/17/2013)... 2013  Yongye International, Inc. (NASDAQ: YONG ... and distributor of crop nutrient products in ... that, on May 16, 2013, the special committee (the ... of Directors") was provided a letter (the "Letter") issued ... ) Limited ("Abax") to Full Alliance International Limited ("Full ...
Breaking Biology Technology:Kitware Enables Interactive Exploration of CMS Medicare Data 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2Breakthrough for IVF? 2Breakthrough for IVF? 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... ST. LOUIS, June 2 SAFC Hitech(TM), a ... Group (Nasdaq: SIAL ),today announced the introduction ... cost-efficient migration path to controlled precursor delivery,for larger ... combined,with increased safety controls., The OM700 offers ...
... expertise, SAN DIEGO, June 2 Trius ... to its Board of Directors. Truex is,the founder, ... as President and CEO of Peninsula Pharmaceuticals where ... $21000000 from a key,strategic partner) and negotiated both ...
... Further ... Clinical Development of tgAAC94, BOSTON and SEATTLE, May 30 ... release earlier today, entitled,"Targeted Genetics Reports Additional Data From Inflammatory ... study of tgAAC94 in patients with inflammatory arthritis. Pervin,Anklesaria, Ph.D., ...
Cached Biology Technology:SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 2SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 3Trius Appoints Paul Truex to Board of Directors 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 2Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings 3
(Date:5/20/2013)... A novel vaccine study from South Dakota State University ... unveiled at the American Association of Pharmaceutical Scientists, (AAPS) ... May 20 - Wednesday, May 22 at the Sheraton ... goal of a vaccine is to stimulate the immune ... disease", explained Dr. Hemachand Tummala, assistant professor of Pharmaceutical ...
(Date:5/20/2013)... of Bristol and published online today in the ... the brain and inner ear developed in dinosaurs. ... together with Tom Hbner from the Niederschsische Landesmuseum in ... old dinosaurs. , The two palaeontologists studied different fossils ... very young (juvenile) individual of approximately three years ...
(Date:5/20/2013)... Boulder, Colo., USA New Geology ... 16 May 2013 cover a wide swath of ... tectonics, oceanography, geophysics, and paleobotany. Locations studied include ... mine at Alpi Apuane, Italy; Ukraine; Mars; and ... , 1. Rubies, jadeite, and plate tectonics;, ...
Breaking Biology News(10 mins):Germ-fighting vaccine system makes great strides in delivery 2Fossil brain teaser 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11
... for the annual infectious diseases meeting of the American ... 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ... Place Convention Center in Chicago, Illinois. ... new information on clinical and basic research in infectious ...
... of a natural body chemical may allow doctors to reduce ... of critically ill patients. "Infection is a common and ... ways to improve the outcomes of sick, elderly patients and, ... Heyland, a professor of Medicine at Queen,s, director of the ...
... the U.S. first responder community,s need for documentary standards ... Institute of Standards and Technology (NIST) Law Enforcement Standards ... to first responders as part of a pilot project ... will help OLES gauge whom needs access to standards ...
Cached Biology News:Finding could reduce antibiotic use in critically ill patients 2It's your standard pilot project: NIST to offer documentary standards to first responders 2
...
... (rEK) is a highly purified preparation of ... serine protease which recognizes the identical cleavage ... has similar enzymatic activity. Novagen&'s enzyme is ... purified to yield the highest activity available, ...
... Affinity purified polyclonal antibody to the ... Goat. Isolated from a serum pool ... Salmonella. This antibody is broadly reactive ... from ATCC. It has excellent specificity ...
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Biology Products: